Trial Profile
A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs Amlodipine (Primary) ; Amlodipine/ezetimibe/losartan/rosuvastatin (Primary) ; Ezetimibe/rosuvastatin (Primary) ; Losartan (Primary)
- Indications Dyslipidaemias; Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Hanmi Pharmaceutical
Most Recent Events
- 03 Jul 2023 Primary endpoint (Change from baseline in sitting systolic blood pressure) has been met, as per results published in the American Journal of Cardiovascular Drugs.
- 03 Jul 2023 Primary endpoint (Change from baseline in LDL-C (%)) has been met, as per results published in the American Journal of Cardiovascular Drugs.
- 03 Jul 2023 Results assessing the efficacy and tolerability of a fixed-dose single-pill combination consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia, published in the American Journal of Cardiovascular Drugs.